Xeris Pharmaceuticals | XERS - Selling And Administration Expenses

Stock Price
7.85
Daily Change
-0.04 -0.51%
Monthly
42.99%
Yearly
212.75%
Q3 Forecast
7.78

Xeris Pharmaceuticals reported $44.39M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 334.69M
Cash and Equivalent USD 59.28M
Cost of Sales USD 11.9M
Current Assets USD 185.58M
Current Liabilities USD 95.17M
Debt USD 257.22M
EBIT USD 5.43M
EBITDA USD 8.59M
Employees 377
EPS Earnings Per Share USD -0.01
Equity Capital and Reserves USD -19.3M
Gross Profit on Sales USD 59.64M
Interest Expense on Debt USD 7.36M
Interest Income USD 948K
Loan Capital USD 218.63M
Market Capitalization USD 1.1B
Net Income USD -1.93M
Operating Expenses USD 67.06M
Operating Profit USD 4.48M
Ordinary Share Capital USD 161.22M
Pre-Tax Profit USD -1.93M
Sales Revenues USD 71.54M
Selling and Administration Expenses USD 44.39M
Stock USD 67.28M
Trade Creditors USD 9.46M
Trade Debtors USD 53.05M

Selling And Administration Expenses Change Date
Adcock Ingram Holdings ZAR 1.05B 50.17M Dec/2024
Celltrion KRW 276.8B 58.09B Mar/2025
Cspc Pharmaceutical CNY 1.89B 347.81M Mar/2025
Dianthus Therapeutics USD 8.87M 2.04M Jun/2025
Divis Laboratories Ltd 3.4B 10M Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Kangmei Pharma CNY 259.36M 49.8M Jun/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
Laboratorios Farma EUR 35.32M 2.75M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 12.94M 5.87M Dec/2024
Neuren Pharmaceuticals AUD 2.33M 47K Dec/2024
Organigram Holdings CAD 25.49M 8.3M Jun/2025
Pacira USD 77.19M 9.58M Jun/2025
Perrigo USD 273.1M 8.1M Jun/2025
Pharma Mar EUR 14.68M 1M Jun/2025
Qiagen NV USD 148.74M 10.8M Jun/2025
Sartorius EUR 225.2M 6.7M Jun/2025
Sino Biopharmaceutical CNY 5.31B 1.54B Dec/2024
Supernus Pharmaceuticals USD 62.22M 27.72M Jun/2025
Tilray USD 72.38M 4.99M Nov/2024
Zz Pientze Pharmaceu -171290000 342.58M Jun/2025